Login
$BBNX
$15.21 -$1.21 (7.37%) Close

$BBNX SEC Filings

Filed On Filing
16 Nov 2026 144
13 Nov 2026 Form 4
12 Nov 2026 Form 4: Feider Stephen, Chief Financial Officer

Received 744 shares by exercise or conversion ($3.79K) · Sold 744 shares ($12.6K)

12 Nov 2026 144
09 Nov 2026 144
09 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 Form 4: Feider Stephen, Chief Financial Officer

Received 382 shares by exercise or conversion ($1.95K) · Sold 382 shares ($6.51K)

05 Nov 2026 144
04 Nov 2026 Form 4: Hopman Mark, Chief Commercial Officer

Sold 370 shares ($6.25K)

29 Oct 2026 Form 4: Mensinger Mike, Chief Product Officer

Sold 2,650 shares ($58.3K)

28 Oct 2026 Form 4: Hopman Mark, Chief Commercial Officer

Sold 821 shares ($16.4K)

27 Oct 2026 10-Q
27 Oct 2026 8-K: Results of Operations and Financial Condition

IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 3...

16 Oct 2026 Form 4: Hopman Mark, Chief Commercial Officer

Sold 775 shares ($13.4K)

07 Oct 2026 SCHEDULE 13G
05 Oct 2026 Form 4: Hopman Mark, Chief Commercial Officer

Sold 370 shares ($7.02K)

01 Oct 2026 144
23 Sep 2026 Form 4: Jones Christy, Director

Sold 6,430 shares ($148K)

22 Sep 2026 144
18 Sep 2026 Form 4/A: Hopman Mark, Chief Commercial Officer

Sold 35,994 shares ($665K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support